T-VEC in Combination with Ipilmumab for Melanoma Treatment
Igor Puzanov, MD, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the rationale behind a phase Ib study to evaluate the efficacy and safety of T-VEC and ipilimumab in previously untreated, unresected stage IIIB-IV melanoma
Igor Puzanov, MD, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the rationale behind a phase Ib study to evaluate the efficacy and safety of T-VEC and ipilimumab in previously untreated, unresected stage IIIB-IV melanoma.
Clinical Pearls:
- Researchers used T-VEC, an oncolytic virus, because of previous positive data.
- T-VEC can unleash multiple antigens from the lysine tumor regardless of the tumor genotype. These antigens will then be presented to the dendritic cells, which are driven to the event from T-VEC.
- These dendritic cells teach T cells to start killing the tumor locally and hopefully throughout the body. In order to augment a response throughout the body, ipilimumab is used.
- Although ipilimumab helps 25% of patients live longer and have long durable responses, sometimes these responses are slow. Adding T-VEC may help speed up the responses in a safe manner.
Response Time and BRAF Status Factor Into IO Selection for Melanoma
January 29th 2025During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 affect their choice of therapy for metastatic melanoma in the first article of a 2-part series.
Read More
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
